SABCS 2022 | New insights into endocrine therapy treatment response and resistance

Lajos Pusztai, MD, Yale School of Medicine, New Haven, CT, provides an overview of a session on endocrine therapy resistance and biomarkers that can help select patients who can benefit from CDK4/6 inhibitors. Data presented at the San Antonio Breast Cancer Symposium (SABCS) 2022 suggested different ER-positive subtypes could derive various benefit with different endocrine intensification strategies. Results of the Phase III PENELOPE-B (NCT01864746) and PALOMA-2 (NCT01740427) and PALOMA -3 (NCT01942135) trials failed to demonstrate benefit with palbociclib. However, a subgroup of patients with Luminal A HER2-negative breast cancer with high HER2 mRNA expression appeared to be driving benefit from palboclib. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.